FDA announces changes to risk strategy requirements for 2 drugs
FDA announces changes to risk strategy requirements for 2 drugs to treat low platelet counts
Nplate, Promacta, REMS
« FDA approves first cord blood product The U.S. Food and | Main | FDA Approvals - MonoSol Rx Announces Listing of Patent in FDA Orange Book »